Navigation Links
Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
Date:8/19/2007

Levodopa Remains the Most Widely Prescribed Drug for Parkinson's Disease,

According to a New Report from Decision Resources

WALTHAM, Mass., Aug. 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that 61 percent of newly diagnosed Parkinson's disease patients do not receive any drug treatment in the first year of diagnosis. According to the new report entitled Treatment Algorithms for Parkinson's Disease, failure of newly diagnosed Parkinson's disease patients to receive pharmacological treatment within the first 12 months of diagnosis likely occurs as a result of patients' decisions to delay treatment until symptoms become sufficiently troublesome. Furthermore, because the guidelines of the American Academy of Neurology (AAN) do not define specific time periods for when treatment should be initiated, patients may be reluctant to begin levodopa therapy, such as with Bristol Myers Squibb's Sinemet, knowing that side-effects will arise, specifically motor response complications.

Levodopa provides greater motor benefit than dopamine agonists, such as GlaxoSmithKline's Requip or Boehringer Ingelheim's Mirapex, but inevitably results in the development of levopoda-induced side effects, including dyskinesias, off time (sudden motor switches between normal and Parkinson movements) and wearing-off complications (shortened periods of benefit after each levodopa use).

"Levodopa continues to be the gold-standard Parkinson's disease treatment, with 99% of neurologists and 95% of PCPs we surveyed currently prescribing it in their Parkinson's disease practice," said Nicole Westphal, Ph.D., analyst at Decision Resources. "However, first-line levodopa use will decrease over the next two years as physicians increasingly use levodopa-sparing approaches. Patient demand for well-tolerated, levodopa-sparing treatments will continue to drive increases in dopamine agonist patient share first line. Patients will benefit from the introduction of new agents, including new formulations and line extensions within the dopamine agonist class. However, GlaxoSmithKline's Requip will face generic competition in 2008, so the overall market for dopamine agonists will begin to diminish, despite the launch of new agents in this class."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithms Insight Series provides:

-- Summary of U.S. medical practice based on interviews with leading

experts in the field

-- Qualitative diagnosis/referral/treatment algorithm for the

United States

-- Drug usage by lines of therapy (1st, 2nd, 3rd line)

-- Discussion of key freeform combinations by lines of therapy

-- Product share (class and specific compound level) within each line of

therapy (1st, 2nd, 3rd line)

-- Progression of therapy from key 1st line products

-- Pathway to key therapies from previous therapies

-- Qualitative analysis of 2-year forecast incorporating upcoming

launches, changes in reimbursement, etc.

About Decision Resources

Decision Resources, Inc., (http://www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources

Copyright©2007 PR Newswire.

Related medicine technology :

1. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
5. Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free Survival by 45 Percent in Patients With Intermediate-Risk Kidney Cancer
6. Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18
7. Waismann Method Survey Reveals 65 Percent of Women Seeking Opiate Dependency Treatment Are Mothers
8. Eighty-one Percent of U.S. Adults say that Birth Control Pills and Procedures Should Be Covered by Health Insurance
9. Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years
10. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
11. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Research and Markets has announced the addition of ... report to their offering. ... This research service on the global pharmaceutical stability ... a snapshot of the key participants in the market. ... 2016 to 2020. The market is expected to grow at a ...
(Date:1/19/2017)... LONDON , Jan. 19, 2017 ... 2022 Summary GlobalData,s new report, "Germany Cataract ... data on the Germany Cataract Surgery Devices market. The ... (in units) and average prices (USD) within market segements ... The report also provides company shares and distribution shares ...
(Date:1/19/2017)... WASHINGTON , Jan. 19, 2017 Conference Call and ... VNDA ) today announced it will release results for the ... market closes. ... Vanda will host a conference call at 4:30 PM ET on ... quarter and full year 2016 financial results and other corporate activities. ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... January 21, 2017 , ... Seamild, the largest manufacturer of oats in ... its owner and founder. As Oat is recognized globally as one of the healthiest ... as he believes it is a move to sow the seed of good karma. ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... Dianne Travis-Teague, the electrifying line-up of events for its annual meeting “Coming Home ... and community. “Coming Home 2017” will be held on Friday January 27 ...
(Date:1/21/2017)... Santa Rosa, CA (PRWEB) , ... January 21, ... ... announce the opening of its new medical office in Petaluma, located at 167 ... full-service casting room, access to SRO sports medicine and rehabilitation services ...
(Date:1/21/2017)... ... 21, 2017 , ... The Nobel Biocare™ dental implant company ... for its creos™ line of bone regenerative products. Specifically, the Nobel ... utilizes creos™ allo.gain™ bone graft for a variety of bone reconstruction procedures. In ...
(Date:1/20/2017)... MD (PRWEB) , ... January 20, 2017 , ... A ... to donate items they no longer use or need, from clothes to couches to ... any unwanted items and take them to the nearest Goodwill donation center through February ...
Breaking Medicine News(10 mins):